McGuireWoods partner and host Geoff Cockrell and associate Amanda Roenius welcome Jessica Nunn, CEO of Maven Financial Partners, for a discussion about the convergence of med spas and private equity.

Jessica describes key characteristics of the med spa arena, different membership models and drivers of profitability and explains why she expects the space to be more competitive in 2025.

☑️ Jessica Nunn | LinkedIn

☑️ Maven Financial Partners | LinkedIn

☑️ Amanda Roenius | LinkedIn

☑️ Geoff Cockrell | LinkedIn

☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X

☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

Med spas are rapidly becoming the front door to healthcare, and Empower Aesthetics has put out the welcome mat.

Partnering with financial sponsor Shore Capital, Empower’s platform of medical spas are located in Texas and Tennessee and building in the Midwest and upstate New York. With host Geoff Cockrell, Empower’s CEO Alyssa Rapp and Shore’s Logan Pitts share their insights on growing a med spa platform. She attributes Empower’s success to a relentless focus on “pure-play med spa” that offers injectables, lasers, and body contouring. “We’re sticking to our knitting and very clear on what we’re doing,” she says.

☑️ Alyssa Rapp | LinkedIn

☑️ Empower Aesthetics | LinkedIn | Instagram

☑️ Logan Pitts | LinkedIn

☑️ Shore Capital Partners | LinkedIn

☑️ Geoff Cockrell | LinkedIn

☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X

☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

As the pharma services sector grows, regulators at the Department of Justice and Food and Drug Administration are placing everything from clinical trials to site management under the microscope. McGuireWoods partner Clint Narver speaks from experience: He joined the firm after serving in leadership roles at both agencies.

With host Geoff Cockrell, Clint helps industry stakeholders understand regulators’ enforcement priorities. He covers the responsibilities of clinical research organizations (CROs), the impact of decentralized clinical trials on regulatory oversight, and the importance of corporate compliance in avoiding enforcement actions. To investors looking at acquiring a company, Clint notes that DOJ’s recent Mergers and Acquisitions Safe Harbor policy is designed to incentivize the disclosure of corporate crime that is uncovered through the due diligence process. 

☑️ Clint Narver I LinkedIn

☑️ Geoff Cockrell | LinkedIn

☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X

☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

At fast-growing Allied Digestive Health, with 194 GI physicians, 75 nurse practitioners, and locations in New Jersey and New York, COO Sap Sinha is excited about the future.

“Private equity in general is looking at GI very specifically, and there are multiple reasons for it,” Sap says in this conversation with host Geoff Cockrell. One reason lies in the fact that colon cancer is the second-largest cancer or cause of death in the United States. Sap describes the current landscape, where Allied is investing in clinical quality and partnering with large institutions, as well as frontiers, such as genetics to detect colon cancer and helping obese patients reduce weight to manage non-alcoholic fatty and liver disease.

☑️ Sap Sinha | LinkedIn

☑️ Allied Digestive Health

☑️ Geoff Cockrell | LinkedIn

☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X

☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

Host Geoff Cockrell invites Steve DeLong, founder and co-CEO of Bluetree Dental, to discuss growing a DSO in a competitive healthcare landscape. Bluetree, which has expanded to more than 40 offices across six states since its inception in 2012, represents a successful model of combining de novo growth with acquisitions. Steve emphasizes the importance of maintaining a balance between central guidance and local practice autonomy, ensuring that dental professionals retain a degree of control over their operations. Geoff and Steve also cover the strategic alignment of interests between a DSO and its dental providers, detailing Bluetree's approach to equity ownership and partnership models. Finally, Steve shares insights about Bluetree's decision to partner with Clairvest Group for a minority private equity investment, highlighting the desire for a cautious, long-term growth strategy over rapid expansion. 

☑️ Steve DeLong | LinkedIn

☑️ Bluetree Dental I LinkedIn I Instagram I Facebook

☑️ Geoff Cockrell | LinkedIn

☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X

☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

Host Geoff Cockrell observes that seller anxiety about the potential for broken deals seems to be high right now. A surprising number of deals, he says, are reluctant to “go out into a wider market process.” Guest Reed Van Gorden of Deerpath Capital sees the same trend: mergers and business sales are slow. He’s waiting to see if the two additional interest rate cuts that are expected this year will set more deals in motion.

Reed finds that companies are performing well and have stabilized since the effects of the COVID pandemic. And the local businesses that Deerpath focuses on, such as medical offices, are not terribly affected by world events like supply chain problems or fluctuating oil prices.

☑️ Reed Van Gorden | LinkedIn

☑️ Deerpath Capital | LinkedIn

☑️ Geoff Cockrell | LinkedIn

☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X

☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

The US Department of Justice has annunciated several enforcement priorities relevant to the healthcare sector: senior care, opioids, cyber security and privacy, and – of particular interest to listeners of “The Corner Series” – private equity investors in the healthcare space.

Michael Podberesky, a former DOJ prosecutor who is now co-chair of McGuireWoods’ False Claims Act Investigations, Litigation and Enforcement team, outlines these priorities in this installment of “The Professor’s Corner,” a special episode where “The Corner Series” host Geoff Cockrell invites experienced practitioners to share insight about nuanced topics. Michael offers an insider’s view of the agency, including how it balances political pressure with its evidentiary burden and how its attorneys triage the large number of complaints they receive. He also observes that his former DOJ colleagues typically have one overriding calculus: “Am I dealing with a bad actor?” For the most part, they are fair and reasonable, he says, adding: “That doesn't mean we’re going to agree, and it doesn’t mean our listeners are going to agree.”

☑️ Michael J. Podberesky | LinkedIn

☑️ Geoff Cockrell | LinkedIn

☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X

☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

The business-side of running an oral and maxillofacial surgery practice can present unique challenges, such as purchasing the latest equipment, staffing offices and dealing with technology and cyber security. That’s where private equity and a group run by doctors tries to help.

Listen as Daniel Hosler, who brings experience in equity, and Dr. David Kostohryz, Jr., an oral surgeon, discuss Allied OMS, an oral and maxillofacial surgery platform they founded that helps with the “business of the business” of oral surgery offices.

Their platform helps offices purchase equipment, staff their offices, keep up with rules and regulations, communicate with other doctors who are part of Allied OMS through a Slack channel, receive some mentoring, and help with IT. And the group helps open satellite offices to expand the services of respected practices.

☑️ Daniel Hosler | LinkedIn

☑️ David Kostohryz, Jr. | LinkedIn

☑️ Allied OMS | LinkedIn

☑️ Geoff Cockrell | LinkedIn

☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X

☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

Everyone wants to dip their toe in the medical aesthetics space, and why not? It’s beautiful. But among platforms in this space, such as day spas, it’s the pure med spa that has longevity “because it mixes the experiential with the service and the clinical outcomes,” says Nicole Chiaramonte​  

In October 2022, Nicole founded Advanced MedAesthetic Partners, which now has 62 locations operated by “young, motivated entrepreneurs” who are hungry to grow their one or two locations into more. The partners are integrated under one umbrella, with standardized back office functions but individualized local patient experiences. With host Geoff Cockrell, Nicole explains AMP’s strategies for expansion and discusses one of the biggest trends in med spa: weight loss drugs. She also shares insights about risks in the industry, including competition, drying up of credit, and state legislation. As AMP approaches its two-year mark, she’s optimistic about what 2025 will bring. 

☑️ Nicole Chiaramonte​ | LinkedIn

☑️ Advanced MedAesthetic Partners | LinkedIn | Instagram 

☑️ Geoff Cockrell | LinkedIn

☑️ McGuireWoods | LinkedIn | Facebook | Instagram | X

☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

This podcast was recorded and is being made available by McGuireWoods for informational purposes only. By accessing this podcast, you acknowledge that McGuireWoods makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in the podcast. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of McGuireWoods. This podcast should not be used as a substitute for competent legal advice from a licensed professional attorney in your state and should not be construed as an offer to make or consider any investment or course of action.

On this cross-over episode of Deal by Deal and The Corner Series, McGuireWoods’ partners Greg Hawver and Geoff Cockrell welcome labor and employment partner Meghaan Madriz to discuss recent headlines regarding the FTC’s proposed ban and the broader legal landscape for non-competes.

Tune in as Meghaan breaks down the evolving enforceability of restrictive covenants, including non-competes tied to employment agreements, sales of businesses, and equity ownership. She also highlights trends in state-specific legislation and shares insights from her experience litigating these issues. The conversation covers how businesses can use alternative tools, such as deferred compensation or retention bonuses, to retain employees amidst increasing scrutiny of non-competes.